文献速递外周动脉疾病

早发外周动脉疾病患者下肢血运重建术后的抗凝治疗

Anticoagulation in Patients with Premature Peripheral Artery Disease Undergoing Lower Extremity Revascularization.
PubMed 文献 · Ann Vasc Surg · 2024-04-07

本研究基于血管质量倡议(VQI)数据库,比较早发外周动脉疾病(PAD,≤50岁行下肢血运重建)患者术后单用抗血小板与抗凝联合抗血小板治疗的结局。倾向评分匹配(2:1)后,抗凝组手术室重返率(3.7% vs 1.6%,P<0.001)和围术期死亡率(1.1% vs 0.3%,P=0.032)更高,1年无截肢生存率更低(80.9% vs 87.5%,log-rank P=0.001)。

要点

  • 匹配后抗凝联合抗血小板组手术室重返率3.7%,高于单用抗血小板组的1.6%(P<0.001)。
  • 匹配后抗凝组围术期死亡率1.1%,高于单用抗血小板组的0.3%(P=0.032)。
  • 1年无截肢生存率抗凝联合抗血小板组80.9%,低于单用抗血小板组的87.5%(log-rank P=0.001)。

核心结论

  • 早发PAD患者下肢血运重建术后在抗血小板治疗基础上加用抗凝与1年再干预和死亡率增加相关。

研究设计与样本

  • 基于血管质量倡议(VQI)外周血管介入、腹股沟下和腹股沟上数据库的回顾性分析,纳入术前及术后单用抗血小板治疗者8,804例和抗凝联合抗血小板治疗者1,236例,按2:1进行倾向评分匹配。

主要发现

  • 匹配前,抗凝组较单用抗血小板组更多合并冠心病(48.7% vs 41.2%,P<0.001)、充血性心力衰竭(20.2% vs 13.1%,P<0.001)和既往下肢血运重建史(73.9% vs 49.2%,P<0.001),独立行走比例更低(74.2% vs 81.8%,P<0.001),他汀使用率更低(66.8% vs 74.3%,P<0.001),因跛行治疗比例更低(38.1% vs 48.6%,P<0.001),接受腔内手术比例更低(64.8% vs 73.8%,P<0.001)。
  • 匹配后单用抗血小板组1,256例、抗凝组628例;抗凝组手术室重返率3.7% vs 单用抗血小板组1.6%(P<0.001),围术期死亡率1.1% vs 0.3%(P=0.032),大截肢率1.8% vs 1.6%(P=0.798),差异无统计学意义。
  • 1年无截肢生存率单用抗血小板组87.5% vs 抗凝联合抗血小板组80.9%(log-rank P=0.001),单用抗血小板组更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Premature peripheral artery disease (PAD), defined by lower extremity revascularization (LER) at age ≤ 50 years, is associated with poor major adverse limb events. The early onset of disease is thought to be influenced by genetic factors that regulate homeostasis of the vascular wall and coagulation. The aim of this study is to investigate the effect of anticoagulation as an adjunct to antiplatelet therapy on the outcomes of LER in patients with premature PAD. METHODS: There were 8,804 patients with premature PAD on preoperative and postoperative antiplatelet therapy only and 1,236 patients on preoperative and postoperative anticoagulation plus antiplatelet therapy in the Vascular Quality Initiative peripheral vascular intervention, infrainguinal, and suprainguinal files. Propensity score matching (2:1) was performed between patients with premature PAD who were on antiplatelet therapy and those on anticoagulation plus antiplatelet therapy. Perioperative and 1-year outcomes were analyzed including reintervention, major amputation, and mortality. RESULTS: Patients on anticoagulation were more likely to have coronary artery disease (48.7% vs. 41.2%, P < 0.001), congestive heart failure (20.2% vs. 13.1%, P < 0.001), and have undergone prior LER (73.9% vs. 49.2%, P < 0.001) compared to patients on antiplatelet therapy only. They were also less likely to be independently ambulatory (74.2% vs. 81.8%, P < 0.001) and be on a statin medication (66.8% vs. 74.3%, P < 0.001) compared to patients on antiplatelet therapy only. Patients on anticoagulation were also less likely to be treated for claudication (38.1% vs. 48.6%, P < 0.001), and less likely to be treated with an endovascular procedure (64.8% vs. 73.8%, P < 0.001). After matching for baseline characteristics, there were 1,256 patients on antiplatelet therapy only and 628 patients on anticoagulation. Patients on anticoagulation were more likely to require a return to the operating room (3.7% vs. 1.6%, P < 0.001) and had higher perioperative mortality (1.1% vs. 0.3%, P = 0.032), but major amputation was not significantly different (1.8% vs. 1.6%, P = 0.798) compared to patients on antiplatelet therapy alone. At 1 year, amputation-free survival was higher in patients on antiplatelets only compared to patients on anticoagulation and antiplatelet medications (87.5% vs. 80.9%, log-rank P = 0.001). CONCLUSIONS: Anticoagulation in addition to antiplatelet therapy in patients with premature PAD undergoing LER is associated with increased reintervention and mortality at 1 year.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kim TI, DeWan A, Murray M, et al. Anticoagulation in Patients with Premature Peripheral Artery Disease Undergoing Lower Extremity Revascularization. Ann Vasc Surg. 2024. PMID: 38593922. doi:10.1016/j.avsg.2024.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。